Drug Profile
Elisidepsin
Alternative Names: Elisidepsin trifluoroacetate; Irvalec; PM 02734; PM-2734Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PharmaMar
- Class Antineoplastics; Depsipeptides
- Mechanism of Action ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 09 Apr 2012 Suspended - Phase-I for Solid tumours (combination therapy) in Spain (IV)
- 09 Apr 2012 Suspended - Phase-I for Solid tumours in USA (IV)
- 09 Apr 2012 Suspended - Phase-II for Gastric cancer in France (IV)